Table 2.
Comparison of measurements between baseline and 12 weeks after treatment with dapagliflozin (N = 27)
| Baseline | 12 weeks | Change | p value | |
|---|---|---|---|---|
| HbA1c (%) | 7.44 ± 0.56 | 6.70 ± 0.57 | −0.75 ± 0.38 | <0.01 |
| Body weight (kg) | 90.9 ± 16.5 | 87.1 ± 15.9 | −3.8 ± 3.2 | <0.01 |
| eGFR (mL/min/1.73 m2) | 91.6 ± 22.3 | 89.5 ± 21.9 | −2.1 ± 8.1 | 0.19 |
| Sodium (mEq/L) | 142.0 ± 2.1 | 141.0 ± 2.3 | −1.0 ± 0.2 | <0.05 |
| Potassium (mEq/L) | 4.2 ± 0.4 | 4.2 ± 0.4 | 0 ± 0 | 0.87 |
| Acetoacetic acid (μmol/mL) | 22.1 ± 9.6 | 35.5 ± 26.9 | 13.4 ± 29.61 | <0.01 |
| 3-hydroxybutyric acid (μmol/mL) | 38.2 ± 14.4 | 73.9 ± 69.0 | 35.7 ± 68.3 | <0.01 |
| Total ketone bodies (μmol/mL) | 60.3 ± 20.8 | 109.4 ± 94.7 | 49.1 ± 94.1 | <0.01 |
| High-sensitivity CRP (ng/mL) | 2410 ± 2814 | 1607 ± 1960 | −803 ± 1080 | <0.01 |
| Adiponectin (μg/mL) | 5.1 ± 2.3 | 6.7 ± 4.2 | 1.7 ± 2.7 | <0.01 |
| PAI-1 (mg/mL) | 30.0 ± 16.8 | 26.8 ± 30.1 | −3.2 ± 32.5 | 0.07 |
Data are expressed as mean ± standard deviation
HbA1c hemoglobin A1c, eGFR estimated glomerular filtration rate, CRP C-reactive protein, PAI-1 plasminogen activator inhibitor-1